Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Clinical trial NCT00503685 · COMPLETED

Trial details

NCT number

NCT00503685

Sponsor

Eli Lilly and Company

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2007-06-01

Primary completion

2009-03-01

Enrollment

65

View on ClinicalTrials.gov